No association was observed between serious infection risk and Janus kinase inhibitor use in patients with immune-mediated inflammatory skin disease.

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

Incyte's infringement lawsuit is claiming that Sun Pharma's drug infringes a US patent (No. 9,662,335) it holds on the use of ...

Lilly and Incyte's already-marketed JAK inhibitor Olumiant (baricitinib) is currently in the lead among drugs for alopecia areata, with a filing due in the second half of this year after two ...

Emkay Global Financial Services, in a client note, described the development as “materially positive,” as it removes a key ...

An autonomous total body photographic (TBP) and dermoscopic imaging device achieved comparable image quality and faster acquisition times than manual dermoscopy, in a prospective cohort study ...

Continuous glucose monitoring (CGM) devices may overestimate blood glucose levels in healthy adults, potentially leading to unnecessary dietary changes and confusion among users, according to a ...

She took me to a dermatologist who prescribed steroid injections. That was the first time I heard the words, "Alopecia areata." I was 12, but, back then, it felt manageable—I could easily hide ...

Janus kinase (JAK) inhibitors are associated with an increased risk for lung cancer but not overall cancer among older patients in the United States with rheumatoid arthritis (RA), according to study ...

2022 — Researchers have discovered that a signaling molecule called SCUBE3 potently stimulates hair growth and may offer a therapeutic treatment for androgenetic alopecia, a common form of hair ...

Management can shift the equity weighting from 40% to 70% of assets, though in practice the team seldom drops equity exposure below 50% and the neutral weight is 60%. The equity and bond managers ...